JPY1,536.50
0.52% yesterday
Tokyo, Dec 30, 07:07 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Target price 2024 - Analyst rating & recommendation

Astellas Pharma Classifications & Recommendation:

Buy
47%
Hold
47%
Sell
7%

Astellas Pharma Price Target

Target Price JPY1,935.71
Price JPY1,534.50
Potential
Number of Estimates 14
14 Analysts have issued a price target Astellas Pharma 2025 . The average Astellas Pharma target price is JPY1,935.71. This is higher than the current stock price. The highest price target is
JPY2,400.00 56.40%
register free of charge
, the lowest is
JPY1,400.00 8.77%
register free of charge
.
A rating was issued by 15 analysts: 7 Analysts recommend Astellas Pharma to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2025 of . Most analysts recommend the Astellas Pharma stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Revenue Billion JPY 1,603.67 1,801.84
5.60% 12.36%
EBITDA Margin 20.95% 18.12%
18.68% 13.49%
Net Margin 1.06% 4.12%
83.41% 288.52%

13 Analysts have issued a sales forecast Astellas Pharma 2025 . The average Astellas Pharma sales estimate is

JPY1.8t
Unlock
. This is
1.68% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
JPY1.8t 3.83%
Unlock
, the lowest is
JPY1.7t 2.76%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 JPY1.6t 5.60%
2025
JPY1.8t 12.36%
Unlock
2026
JPY1.9t 3.30%
Unlock
2027
JPY2.0t 6.77%
Unlock
2028
JPY1.9t 3.69%
Unlock
2029
JPY1.7t 9.23%
Unlock

10 Analysts have issued an Astellas Pharma EBITDA forecast 2025. The average Astellas Pharma EBITDA estimate is

JPY326b
Unlock
. This is
15.68% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
JPY430b 10.99%
Unlock
, the lowest is
JPY264b 31.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 JPY336b 14.13%
2025
JPY326b 2.81%
Unlock
2026
JPY393b 20.41%
Unlock
2027
JPY476b 21.14%
Unlock
2028
JPY488b 2.55%
Unlock
2029
JPY532b 8.96%
Unlock

EBITDA Margin

2024 20.95% 18.68%
2025
18.12% 13.49%
Unlock
2026
21.12% 16.56%
Unlock
2027
23.96% 13.45%
Unlock
2028
25.51% 6.47%
Unlock
2029
30.63% 20.07%
Unlock

6 Astellas Pharma Analysts have issued a net profit forecast 2025. The average Astellas Pharma net profit estimate is

JPY74.2b
Unlock
. This is
35.39% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
JPY109b 98.37%
Unlock
, the lowest is
JPY51.9b 5.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 JPY17.0b 82.49%
2025
JPY74.2b 336.11%
Unlock
2026
JPY138b 86.44%
Unlock
2027
JPY208b 50.77%
Unlock
2028
JPY193b 7.30%
Unlock
2029
JPY138b 28.71%
Unlock

Net Margin

2024 1.06% 83.41%
2025
4.12% 288.52%
Unlock
2026
7.43% 80.34%
Unlock
2027
10.49% 41.18%
Unlock
2028
10.10% 3.72%
Unlock
2029
7.93% 21.49%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Mar '24 2025
Estimates
Earnings Per Share JPY 9.50 41.43
82.49% 336.11%
P/E 37.28
EV/Sales 1.95

6 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

JPY41.43
Unlock
. This is
35.39% higher
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
JPY60.70 98.37%
Unlock
, the lowest is
JPY29.00 5.23%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 JPY9.50 82.49%
2025
JPY41.43 336.11%
Unlock
2026
JPY77.24 86.43%
Unlock
2027
JPY116.45 50.76%
Unlock
2028
JPY107.95 7.30%
Unlock
2029
JPY76.96 28.71%
Unlock

P/E ratio

Current 50.48 43.42%
2025
37.28 26.15%
Unlock
2026
20.00 46.35%
Unlock
2027
13.26 33.70%
Unlock
2028
14.31 7.92%
Unlock
2029
20.07 40.25%
Unlock

Based on analysts' sales estimates for 2025, the Astellas Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.98 17.50%
2025
1.95 1.62%
Unlock
2026
1.89 3.20%
Unlock
2027
1.77 6.34%
Unlock
2028
1.83 3.83%
Unlock
2029
2.02 10.17%
Unlock

P/S ratio

Current 1.56 20.61%
2025
1.53 1.65%
Unlock
2026
1.49 3.20%
Unlock
2027
1.39 6.34%
Unlock
2028
1.44 3.82%
Unlock
2029
1.59 10.17%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today